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Abstract: 
         Changes in angiogenesis and expression of extracellular matrix-degrading enzymes have 
been substantiated during tumor changeover and progression. This study was carried out on 60 
retrospective  endometrial  endometrioid  carcinoma  (EEC)  cases  in  addition  to  15  normal 
endometrial biopsies as controls. EEC cases were grouped according to both histological grade 
(G), from G1 to G3, and the depth of myometrial (M) invasion, from M1 to M3. The study 
investigated  all  cases  immunohistochemically  to  determine  their  microvessel  number  and  the 
expression  of  matrix  metalloproteinase-9  (MMP-9)    and  showed  significantly  high  counts  in 
EEC as a whole over the control endometria (P < 0.001). Moreover counts of the G1 group 
overlapped those of the control endometra, increased significantly (P < 0.01) in the G2 and even 
more  in the G3 group. G3 cases, in particular, displayed most microvessels widely scattered in 
the tumor tissue, in close association with tumor cells and as winding and arborized tubes, often 
dilated in microaneurysmatic segments. The counts also increased in M2 and M3 (P < 0.001) while 
those  of  the  M1  group  overlapped  the  counts  of  control  endometria.  Expression  of  MMP-9, 
evaluated as percentages of positive cases, revealed that the overall EEC cases gave a significant 
increase   (P < 0.01) over the normal control endometria. Also, the frequencies of expression 
were  significantly  increased  with  the  histologic  grade  (P  =  0.01)  and  with  the  depth  of 
myometrial invasion (P = 0.08). The increases for MMP-9 were more evident on transition from 
G2  to  G3  than  from  G1  to  G2.  The  relationship  to  the  depth  of  invasion  revealed  that  the 
increases  for  MMP-9  were  found  at  each  depth,  mostly  on  transition  from  M2  to  M3.  By 
contrast, only two of the control biopsies (13.5%) expressed few MMP-9. In EEC, MMP-9, as 
well, was, expressed by the host stromal cells. 
         These  data  suggest  that  angiogenesis  and  degradation  of  extracellular  matrix  occur 
simultaneously with EEC upgrading and advancing depth of invasion. Also, they suggest that 
EEC cells and some host stromal cell populations cooperate in the tumor progression. 
Key  words:  Angiogenesis,  Matrix  metalloproteinase-9,  Endometrial  neoplasms, 
Endometrioid carcinoma, Tumor invasion, Tumor progression. 
 
Introduction:      
         Angiogenesis;  the  formation  of  new 
blood  microvessels,  is  an  obligatory  event 
connected with  tumor growth  invasion  and 
metastasis
(1).  Faster  growing,  highly 
invasive  and  metastatic  tumors  need  more 
vessels
(2).  The  endothelial  cells  of  
microvessel  sprouts  secrete  important 
paracrine  growth  factors  for  tumor  cells
(3) 
as  well  as  several  extracellular  matrix-
degrading  enzymes  which  allow  spread  of 
the  tumor  cells  into  and  through  the 
adjacent  matrix
(4).  The  new  microvessels 
permit  metastases  because  an  expanding 
endothelial  surface  increases  opportunities 
for tumor cells to enter the circulation
(5). 
         The  additional  events  involved  in 
tumor progression comprise the secretion of 
matrix  metalloproteinases  (MMPs).  The 
MMP family plays an important role in the 
proteolysis  of  various  components  of 
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extracellular  matrix  &  it  includes  type  IV 
collagenases of 72 KDa (MMP-2) and of 92 
KDa (MMP-9) that degrade the type IV, V, 
VII  and  X  collagens  as  well  as 
fibronectin
(4).  Thus,  highly  invasive  tumor 
cells  would  be  expected  to  secrete  large 
amounts of these proteolytic enzymes
(6). 
         There is an evidence that angiogenesis 
is  enhanced  in  keeping  with  the  invasive 
and metastatic phases of solid tumors inclu-
ding colon
(7) , breast
(8) and lung
(9) carcino-
mas  as  well  as  melanoma
(10).  Relationship 
of  this  type  also  hold  true  for  overexp-
ression  of  MMP-9
(11,12).  In  endometrioid 
carcinoma,  however,  the  knowledge  is 
circumstantial.  Angiogenesis  is  associated 
with  tumor  changeover
(13)  and  poor 
histological differe-ntiation; grade 3,
(14) and 
MMP-9, in   particular  is overexpressed  in 
grade 3 and metastatic tumors
(15). 
         This  study,  therefore,  aims  at 
investigating  the  angiogenesis  extent  and 
expression  of  MMP-9  in  endometrial 
endometrioid  carcinoma  (EEC)  biopsies 
and  correlating  them  with  the  tumor 
progression  as  defined  by  the  histologic 
grades  and  the  depth  of  myometrial 
invasion. 
 
Material and Methods: 
         The  study  was  performed  on  sixty 
(60)  retrospective  cases  of  endometrial 
endometrioid  carcinoma  (EEC)  undergoing 
total abdominal hystrectomy, bilateral sapl-
ingo-oophorectomy,  peritoneal  cytology 
and  pelvic  lymph  node  sampling.  Post-
operative  follow-up  (range  16-60  months, 
median  48  months)  consisted  of  pelvic 
examination  and  vaginal  cytology  every 
three  months  for  the  first  two  years  and 
every  six  months  thereafter.  C.T  scan  and 
chest  X-ray  were  performed  yearly.  The 
patient’s age, the tumor stage & grade and 
the  depth  of  myometrial  (M)  invasion  as 
well as the data of post-operative follow-up 
were  obtained  from  the  patient’s  files. 
Additional  fifteen(15)  normal  endometrial 
biopsies  used  as  controls,  were  taken  by 
dilatation  and  curettage  during  the  mid-
secretory  phase,  when  angiogenesis  is  low 
(15), from women (ages 23-44 years), with 
no  apparent  endocrine  dysfunction, 
examined  at  the  Department  of  Obstetrics 
and  Gynecology,  AL-Husein  and  Bab  Al-
Shaariah University Hospitals. All subjects 
gave  their  informed  consent  for  tissue 
collection.  EEC  specimens  were  obtained 
from  the  Pathology  Department,  Al-Azhar 
University  and  Kasr  El-Aini  Hospitals 
during the period (1997-1999). 
         Formalin-  fixed,  paraffin-embedded 
blocks  were  sectioned  at  5µm  thickness. 
One section was stained with Haematoxylin 
and Eosin, for routine histopathologic study 
and  confirmation  of  the  diagnosis. 
Additional  two  sections  were  used  for 
immunohist-ochemical study to analyze the 
microvessel  density  (MVD)  and  MMP-9 
expression.  Murine  monoclonal  primary 
antibodies  for  the  endothelial  cell  marker; 
factor VIII (MoAb M 616, Dako, Glostup, 
Danmark)  and  for  MMP-9  (Fuji  Chemical 
Industries,  Ltd,  Takaoka,  Japan)  were 
applied  each  one  on  a  section.  Antigen 
retrieval was done by microwave heating in 
citrate  solution  (Biogenex-Neufahrn, 
Germany).  Secondary  anti-mouse  antibo-
dies  using  peroxidase  labeled  Biotin 
Streptavidin  Complex  detect-ion  system 
(Dako,  Copenhagen,  Denmark)  were  then 
applied.  Counterstaining  was  performed 
using Mayer’s Haematoxylin. 
 
Assessment of Angiogenesis 
         Care was taken to select microvessels 
e.g. capillaries and small venules, from all 
the  stained  vessels.  A  simultaneous  ident-
ification,  by  two  investigators,  of  these 
microvessels  as  transversally  sectioned 
tubes,  with  a  single  layer  of  endothelial 
cells, either with or without a lumen and not 
exceeding  10µm  in  diameter  was  perfor-
med.  Each  identification  was  agreed  upon 
in  turn.  A  slightly  modified  plani-metric 
point-count  method
(10)  was  used  to  count 
microvessels.  Six  to  eight  160  X  fields 
(0.82mm
2  per  field),  covering  almost  the 
whole  section,  were  analyzed  with  a  144 
point –mesh inserted in the eye piece. The 
microvessel  number  was  calculated  as  the 
total number of the mesh intersection points 
occupied  by  transversally  sectioned 
microvessels.  Because  of  the  small  size  of 
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and  the  sufficient  distance  between  two 
adjacent intersection point, one given point 
could be occupied by only one microvessel. 
In  contrast,  both  the  microvessels 
transversally  sectioned  but  placed  on  the 
inside  or  on  the  sides  of  a  given  small 
square of the mesh and those longitudinally 
or tangentially sectioned, regardless of their 
position,  were  not  counted.  The  mean  +1 
standard deviation, median and range were 
calculated  per  section  and  groups  of 
biopsies. 
 
Immunohistochemistry  (IHC)  of 
MMP-9: 
         The  slides,  prepared  as  described 
previously, were also examined under light 
microscopy  by  two  investigators  indepen-
dently.  For  the  upregulation  of  MMP-9, 
existence  of  more  than  25%  immuno-
reactive cells was considered positive. 
 
Statistical analysis: 
         The  significance  of  changes  in 
microvessel  number  and  MMP-9  expre-
ssion  in  the  groups  of  normal  endometria 
and EEC biopsies was assessed by Fisher’s 
exact test and the non parametric Kruskal-
Wallis  test.  A  linear  regression  test  was 
applied to relate the percentages of MMP-
9-positive & -negative EEC tissues with the 
histological  grades  and  the  depth  of 
myometrial  (M)  invasion.  All  data  were 
analyzed by the Pearson’s Chi-square test. 
A  p-  value  was  found  to  be  statistically: 
Significant if < 0.05; highly significant if < 
0.01; very  highly  significant if  <  0.001  & 
insignificant if  > 0.05. 
 
Results: 
         The  EEC  histological  grades  were 
assessed  according  to  the  International 
Federation  of  Gynecology  and  Obstetrics 
(FIGO)  criteria
(16)  as  (i)  G1  (well 
differentiated), with > 95% of glandular and 
/or papillary structures, including 20 cases, 
(ii)  G2  (moderately  differentiated,  Fig.  1) 
with > 50% of glandular and /or papillary 
structures, including 18 cases, and (iii) G3 
(poorly differentiated, Fig. 2), with > 50% 
solid  areas,  including  22  cases.  The  depth 
of  myometrial  (M)  invasion  was  also 
classified according to the FIGO criteria
(16) 
as  (i)  M1  (22  biopsies),  (ii)  M2  (18 
biopsies)  and  (iii)  M3  (20  biopsies) 
regarding the extension of EEC to the inner 
third, the middle third and the outer third of 
myometrium,  respectively.  There  was  a 
significant  correlation  (P  =  0.05)  between 
the grades and the depth of invasion. Nine 
patients (15%) were found to have positive 
peritoneal  cytology  (FIGO  stage  IIIA)  and 
6  patients  (10%)  have  an  involvement  of 
pelvic  lymph  nodes  (FIGO  Stage  IIIC) 
(Table 1). The follow-up revealed fourteen 
recurrences (23%), all, except two, were in 
the  pelvis.  Six  patients  with  recurrent 
tumors died of the disease between 36 and 
38  months  and  the  remaining  eight  were 
alive  and  well  on  a  follow-up  of  16  –22 
months after diagnosis of recurrence. 
         The number of microvessels in tissues 
from  the  normal  control  endometria  and 
EEC, as a whole and as groups from G1 to 
G3  and  from  M1  to  M3,  were  found  in 
Table  2.  Comparison  between  groups 
revealed  statistically  significant  differences 
(P = 0.004). When the differences between 
groups  were  considered,  there  were  higher 
counts in the overall EEC compared to the 
normal  endometrium  (P  =  0.002).  When 
each grade was compared to the control, no 
significant  difference  was  observed  in  the 
G1  biopsies  whereas  both  G2  and  G3 
biopsies  disclosed  significantly  higher 
counts  (P  =  0.06  and  P  =  0.003, 
respectively).  The  intergrade  comparison 
revealed  that  the  counts  increased  in  the 
function of upgrading, higher counts in G2 
versus  G1  (P  =  0.01)  and  higher  in  G3 
versus G2 (P = 0.05). Regarding the depth 
of  myometrial  (M)  invasion,  the  count  of 
M1  group  overlapped  that  of  the  controls 
but  increased  significantly  (P  =  0.007)  in 
M2  group  and  persisted  in  M3  group. 
Histologically,  microvessels  were  found  in 
all  tissues  as  endothelial  cells,  single  or 
clustered  in  nests  or  tubes,  either  with  or 
without  a  lumen,  not  exceeding  10µm.  In 
control  and  EEC  G1  (Fig.  3)  biopsies, 
microvessels were mainly confined near the 
epithelial  cells  and  only  scarcely  found 
within  the  spared  inflammatory  tissue. 
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biopsies,  they  were  spread  throughout  the 
tumor  tissue.  In  G2  (Fig.  4)  and,  more 
evidently, in  G3  biopsies,  the  microvessels 
could usually be  found as tortuous,  arbor-
ized and anastomosed tubes, some of which 
displayed  microaneurysmatic  dilatations. 
The  pictures  of  this  type  were  rarely 
encountered  in  control  as  well  as  in  G1 
biopsies. 
         The  MMP-9  was  expressed  with  a 
cytoplasmic pattern and in all EEC grades, 
it  was  not  expressed  by  the  whole  tumor 
cell  population  but  by  single  cells  or  cell 
nests  distributed  in  the  tumor  area,  which 
gave  a  very  heterogenous  “ground-glass-
like picture. Also, it was expressed by large 
stromal cells. The number and percentages 
of biopsies expressing MMP-9 were found 
in  Table  3.  The  overall  EEC  gave  a 
significant  increase  (P  =  0.06)  in  the 
frequency  of  MMP-9  expression  over  the 
normal biopsies. Also, the frequencies were 
significantly  increased  with  advancing 
histologic  grading  (P  =  0.01)  and  with 
increasing the depth of myometrial invasion 
(P = 0.08). Increases for MMP-9 were more 
evident on transition from G2 (Fig. 5) to G3 
(Fig. 6) than from G1 to G2. Moreover, the 
relationship  to  the  depth  of  invasion 
revealed that the increases for MMP-9 were 
found  at  each  depth,  mostly  on  transition 
from M2 to M3. By contrast, only two out 
of  the  fifteen  control  biopsies  (13.5%) 
expressed few MMP-9. 
 
 
Table (1): Clinical and histopathological variables of the studied biopsies (n = 60): 
 
*Grade 
(G) 
No; of 
biopsies 
Average age 
(median, range) 
*Stage  * Depth of myometrial (M) 
invasion 
IB  IC  IIA  IIB  IIIA-C  M1  M2  M3 
G1 
G2 
G3 
20 
18 
22 
63 (61,43-81) 
65.5 (62,52-86) 
70.3 (69,63-82) 
8 
8 
2 
3 
1 
9 
3 
3 
2 
3 
2 
1 
3 
4 
8 
14 
4 
4 
3 
7 
8 
3 
7 
10 
* Grade, stage and depth of myometrial (M) invasion were assessed according to the FIGO 
criteria 
(16). 
 
Table (2): Microvessel counts in studied biopsies: 
 
Biopsy  No; of biopsies  No; of microvessels  Per 0.82mm
2 
Means    +    S.D.  (Median; range) 
Normal endometrium  15          3.7        +    1.3  (3        ; 1-10) 
Endometrioid carcinoma:  60          8.9        +     6*  (7        ; 1-26) 
Histologic         Grade 1  20          4.7        +    2.9  (5.5      ; 1-15) 
                         Grade 2  18          8.7        +    5.9  (6.5     ; 4-21) 
                         Grade 3  22          13.8      +    5.1*
●  (12.5    ; 9-26) 
Depth of invasion:       
M1  22          4.7        +     2.8  (5         ;  1-13) 
M2  18          12.2      +     6
●  (12       ; 7-18) 
M3  20          13.0      +     4.0  (12       ; 9-26) 
S.D. = Standard deviation,     * P < 0.001 as compared to normal biopsies  
● P < 0.01 and *
● P < 0.05 as compared to the preceding group. 
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Table (3): Expression of matrix metalloproteinase-9 (MMP-9) by the studied biopsies: 
 
Biopsy  Total No;  MMP-9-positive biopsies 
No;  % 
Normal endometrium  15  2  13.4 
Endometriod carcinoma:  60  22  36.6 
Histologic                   Grade 1*  20  4  20 
                                    Grade 2  18  6  33.3 
                                   Grade 3  22  12  54.5 
Depth of myometrial (M) invasion:       
                                   M1  22  4  18.2 
                                   M2  18  5  27.7 
                                   M3  20  13  65 
*Grade & depth of myometrial invasion were assessed according to the FIGO criteria 
(16). 
 
 
            
             Fig. (1): A case of EEC, grade 2, showing glandular and papillary structures  
                           invading the myometrium                                                  (Hx & E X 100). 
 
 
          
           Fig. (2): A case of EEC, grade 3, showing a solid sheet of pleomorphic malignant  
                        cells with a rudimentary glandular lumen.                        (Hx & E X 400). A Correlative Study of Angiogenesis Extent........ 
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                Fig. (3): A case of EEC, grade 1, showing clusters of microvessels confined 
                               near the malignant epithelial cells.                            (Factor VIII X 200). 
 
 
                Fig. (4): A case of EEC, grade 2, showing arborized and tortuous microvessels  
                               found throughout the tumor tissue.                             (Factor VIII  X 100) 
 
   
Fig. (5): A case of EEC, grade 2, positive for MMP-9 immunoreactivity 
                               (Brownish cytoplasmic immunostaining).         
                                                                 (Immunoperoxidase [IP]   X 100). 
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               Fig. (6): A case of EEC, grade 3, positive for MMP-9 immunoreactivity.     
                                                                                                                    (IP   X 200). 
 
Discussion: 
         Angiogenesis  and  MMPs  are 
important  events  in  the  tumor  growth  and 
progression.  G1  to  G3  offer  a  clear 
representation  of  tumor  progression 
because
(16,17): (a) The tumor growth fraction 
(S-phase fraction)  rises significantly  in  the 
transition from  G1 to  G2 and  from G2  to 
G3;  (b)  Clinical  and  morphological  evolu-
tion from one grade to the next is typical. In 
particular,  MMP-9  was  predominantly 
correlated  with  the  pathological  stage  and 
histological grade  in  EEC  which  displayed 
a highly characteristic immunophenotype of 
the endometrial carcinomas
(18). 
         This  study  showed  that  angiogenesis 
extent,  evaluated  as  microvessel  number, 
and the expression of MMP-9 by the tumor 
cells  were  increased  simultaneously  accor-
ding to the advancing histological grade (G) 
and  depth  of  myometrial  (M)  invasion  in 
EEC.  The  microvessel  counts  were  low  in 
G1  (overlapping  those  of  normal  control 
group) and increased significantly in G2 (P 
< 0.01) and even more so in G3 (P< 0.001). 
In addition, the counts in M1 group overl-
apped  those  of  the  control  one,  although 
being significantly  increased  in M2  &  M3 
groups  (P  <  0.001).  These  results  agreed 
with  those  of  Wagatsuma  et  al.,
(14)  who 
found higher counts in G3 versus G1 + G2 
and  in  M2  and  M3  versus  M1,  though 
normal  endometrium  was  not  considered. 
Although  in  situ,  but  not  a  functional, 
assessment was performed in this study,  it 
is  suggested  that  new  microvessels  are 
induced  by  EEC  cells,  whose  angiogenic 
ability  is  enhanced  with  advancing  grades 
or  with  tumor  dedifferentiation.  Angiog-
enesis  could  be  stimulated  directly  or 
indirectly,  after  the  tumor  cells  have 
recruited inflammatory  cells  (macrophages, 
mast  cells  and  lymphocytes)  stimulating 
them  to  secrete  their  own  angiogenic 
factors
(5).  In  addition,  mast  cells,  a 
prominent  stromal  cell  population  in  the 
endometrium
(19),  are  well  recognized  to  be 
involved in the tumor angiogenesis
(20) since 
the tumor cells activate them to produce the 
angiogenic  histamine  and  tryptase 
(21)  as 
well as an array of angiogenic cytokines
(22). 
Neovessels  favour  the  tumor  invasion  and 
metastasis
(5) which could explain why EEC 
G3  tumors  are  more  frequently  metast-
asized to pelvic peritoneum, adnexa, vagina 
and  lymph  nodes  (i.e.  found  in  the  stage 
III), as detected in 8 G3 (36%) versus 4 G2 
(22%)  and  3  G1  (15%)  biopsies  in  the 
present study. These figures coincided with 
those reported by Iurlaro et al.,
 (18) 
         MMP-9  detected  in  this  work  was 
significantly overexpressed from G1 to G3 
biopsies  and  the  increase  in  frequency  of 
tumors  positive  for  MMP-9  was  encoun-
tered with advancing grades (P = 0.01) as 
well as with deeper myometrial invasion (P 
< 0.01). The data, suggest that MMP-9 is 
produced  more  frequently  and  greatly  as 
EEC progresses and hence a degradation of 
the  interstitial  stroma  and  subendothelial 
basement  membrane  is  more  intense  with A Correlative Study of Angiogenesis Extent........ 
  8  
progression.  They  agreed  with  those  of 
Inoue  et  al.,
(15)  who  showed  that  the 
expression of MMP-9 was associated  with 
vessel  invasion,  highest  grade  (G3)  and 
lymph  node  metastasis  and  were  mimicing 
as well, those reported by Iularo et  al.,
(18) 
who could explain the greater dissemination 
and  deepening  of  endometrial  carcinoma 
cells  into  the  myometrial  wall  as  they 
undergo  the  transition  from  G1  to  G3. 
Together  with  denser  angiogenesis,  they 
could  additionally  account  for  easier 
spreading  to  lymph  nodes  and  other 
parenchymal organs with that transition. 
         In  this  study,  all  investigated  EEC 
showed that MMP-9 was also expressed by 
large stromal cells. This finding was similar 
to that reported by Hampton et al 
(23) and 
Osteen  et  al
(24)  who  found  that  certain 
stromal cells in EEC, belonging to a subset 
of  macrophages,  expressed  MMP-9  and 
they  as  well,  produced  additional  matrix-
degrading  enzymes,  such  as  interstitial 
collagenase,  or  MMP-1,  and  stromelysin-1 
or MMP-3, when plasma progesterone and 
estradiol  levels  decline,  thus,  overcoming 
their tissue specific inhibitors (TIMPs) and 
leading  to  tissue  digestion  and  breakdown 
in the last days of the secretory phase and in 
menstruation
(25,26). 
         In the endometrial carcinoma, several 
stromal  cells,  activated  by  tumor  cells, 
produce  MMP-2  and  MMP-9,  thus 
participating  in  the  degradation  of  the 
extracellular  matrix,  and  enhancing  the 
tumor  dissemination
(15).  Together  with  the 
findings  in  other  solid  tumors 
(27,28),  our 
results suggest that the regulation of extrac-
ellular  matrix  degradation  during  tumor 
progression  is  the  result  of  a  concerted 
action  not  only  of  several  proteolytic 
enzyme  systems,  but  also  of  several  cell 
types,  including  both  malignant  and  non-
malignant cells in the neoplastic stroma. 
         In  conclusion  our,  data  show  that 
angiogenesis  and  MMP-9  overexpression 
occur  simultaneously  during  EEC 
progression.  This  suggests  that  there  are 
more  chances  for  these  malignant  cells  to 
enter  the  circulation  and  spread 
systemically  in  parallel  with  progression. 
The  use  of  antiagiogenic  agents
(29)  and/or 
tissue  inhibitors  of  metalloproteinases 
(TIMPs)
 (26) may be a target for therapy. 
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 ميسوا راهظاو ةقيقذلا ةيىمذلا ةيعولأا ذلاىت مجح ةقلاع ةسارد
سيىيتوربىلاتيم - 9    راذجلا ناطرسل ًلضعلا وسغلاو يذعاصتلا جرذتلا عم
محرلل هطبملا  
همحرلا ذبع هسح ذمحأ * -   ملاس ذيعس ذمحأ  * -   ناميلس ذيمحلا ذبع ناىح **  
  ةخيشلا ايركز ذلاخ  *** –   رماع ًماس ذمحأ  *** -   ا حلاص ذمحم هيواسح هيذل ***  
   فورعم فيطللا ذبع دامع ***  
 شْصلأا بط ىخيهكب ىجٕنٕثابنا واسقأ ٍي ( طٕيسا عشف   * ) ةشْاقنا بطٔ ** -    ىسق
 شْصلأا بط تيهكب ذينٕخنأ ءاسُنا ( ةشْاقنا عشف ***)  
  
           سادددٓ   ىدددف  نزددد ٔ ةشيادددانا تدددكٕيذنا تددديػٔلأا ذدددنإح ىدددف ثاشدددياخنا ذدددسجخح
هن تههحًنا ثاًكضَلإا  ِزدْ جدكشجأ ذدقٔ وسٕدنا وذدقحٔ سٕدطح ءاُثأ اكلاخنا ٍيب غقإنا جيسُ
 ىهػ تساسذنا 06    ىدنا تفادةلإاب ىحشدهن ٍطبدًنا ساذدجنا ٌاطشس ٍي تناح 51    ٍدي تدناح
تَساقًنا ميبس ىهػ ىحشهن ىؼيبطنا ساذجنا  .  تدكٕيذنا تديػٔلأا دذػ ٍي م  تساسد ىح ذقٔ
ضيُيحٔشبٕناخيي ىكضَا سآ  ٔ تقيقذنا - 9   ًُناب  ٌأ تدساسذنا ثشدٓ أ ٔ تيةايًي ٕخدسٓنا تدػا
 ادً  ، ىؼيبطنا جيسُنا ىف آُي ٌاطشسنا ثلااح ىف ىهػأ تقيقذنا تكٕيذنا تيػٔلأا داذػا
 ىددؼيبطنا جيددسُنأ  ىددنٔلأا تددجسذنا ٌاطشددس ٍيددب داذددػلأا ىددف معاذددح دٕددجٔ جددُيب اددَٓأ
ُّػ تيَاثنا تجسذنا ٌاطشس ىف تيػٔلأا ِزْ داذػأ داكدصا ًاضكأ ظحٕنٔ    ىدفٔ ىنٔلأا ىف
 ىددف تدديػٔلأا ِزددْ داذددػا ثداص ذددقف  ددنر ىددنا تفاددةلإاب تدديَاثنا ىددف ّددُػ تددثناثنا تددجسذنا
 ىدنٔلأا تدهحشًنا ٌاطشدس ىدف ايأ ىهضؼنا مغٕخنا ٍي تثناثنأ تيَاثنا ٍيخهحشًنا ٌاطشس
ضيُيحٔشبٕناددخيي ىكضددَا ساددٓ تب  ددهؼخك اددًيفٔ ىددؼيبطنا جيددسُنا غددي اْدذددػ معاذددخف - 9    ذددقف
سَ ثدادصا  ثلاذؼي دادضح  نز  ىؼيبطنا جيسُنا ىف ُّي ٌاطشسنا ثلااح ىف ِسآ ا ب
 وذقح ذُػ ًاحٕةٔ شث أ ةداكضنا ٌٕكحٔ ٌاطشسنا مغٕح تهحشئ تجسد ةداكص غي ِسٕٓ 
 تدهحشًنا ٍي ّهغٕح ذُػٔ تيَاثنا ىنا ىنٔلأا ٍئ تثناثنا ىنا تيَاثنا تجسذنا ٍي ٌاطشسنا
ف تددَساقًنابٔ تددثناثنا ىددنا تديَاثنا  ٍددي ظددقف ٍيخناددح ىددف تهيلدة تبددسُب ىكضددَلإا ازددْ شددٓ  ذدق
ىؼيبطنا جيسُنا ثلااح  .  ادكلاخنا ٍدي م  ةشٓظح ىكضَلإا ازْ ٌأ تساسذنا جحةٔأ ًاشيعأ
ىًحهنا جيسُنا اكلاع ضؼبٔ تيَاطشسنا  
           جيدسُنا مدهحح غدي تقيقذنا تكٕيذنا تيػٔلأا ذنإح دٔذح تساسذنا ِزْ ٍي جخُخسَٔ
نا ٍيدب غدقإنا  اددً  ،ٌاطشدسنا مدغٕح تددهحشئ تدجسد ذػاداح غددي جدقٕنا وداَ ىددف ادكلاخ
 ىددف تيَاطشددس شدديانا ىددًحهنا جيددسُنا اددكلاع ضددؼبٔ تيَاطشددسنا اددكلاخنا ٌٔاددؼح جخُخددسَ
واسٔلأا ٍي عُٕنا ازْ لاحاخسا .  
 